Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Catalyst Pharmaceuticals Inc shares valued at $621,920 were sold by Harper Molly on Dec 12 ’25. At $23.25 per share, Harper Molly sold 26,746 shares. The insider’s holdings dropped to 2,360 shares worth approximately $56640.0 following the completion of this transaction.
Also, Harper Molly purchased 26,746 shares, netting a total of over 621,929 in proceeds.
Before that, Del Carmen Jeffrey had sold 10,983 shares from its account. In a trade valued at $256,244, the Chief Commercial Officer traded Catalyst Pharmaceuticals Inc shares for $23.33 each. Upon closing the transaction, the insider’s holdings decreased to 10,983 shares, worth approximately $95088.0.
As published in their initiating research note from Robert W. Baird on February 04, 2025, Catalyst Pharmaceuticals Inc [CPRX] has been an Outperform and the price target has been revised to $28. Analysts at Stephens started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid November. As of March 14, 2024, Citigroup has initiated its “Buy” rating for CPRX. Earlier on March 07, 2024, BofA Securities initiated its rating. Their recommendation was “a Buy” for CPRX stock.
Analyzing CPRX Stock Performance
On last trading session, Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] plunged -0.79% to $24.0. The stock’s lowest price that day was $23.88, but it reached a high of $24.4513 in the same session. During the last five days, there has been a surge of approximately 5.26%. Over the course of the year, Catalyst Pharmaceuticals Inc shares have jumped approximately 12.25%. Shares of the company reached a 52-week high of $26.58 on 06/09/25 and a 52-week low of $19.05 on 09/25/25.
Support And Resistance Levels for Catalyst Pharmaceuticals Inc (CPRX)
According to the 24-hour chart, there is a support level at 23.77, which, if violated, would cause prices to drop to 23.54. In the upper region, resistance lies at 24.34. The next price resistance is at 24.68. RSI (Relative Strength Index) is 62.51 on the 14-day chart, showing neutral technical sentiment.
Is Catalyst Pharmaceuticals Inc subject to short interest?
Stocks of Catalyst Pharmaceuticals Inc saw a sharp rise in short interest on 2025-11-28 jumping by 12953.0 shares to 7.94 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 7.92 million shares. A jump of 0.16% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.77 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.77.
Which companies own the most shares of Catalyst Pharmaceuticals Inc (CPRX)?
In terms of Catalyst Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 33 in the next 12 months, up nearly 36.42% from the previous closing price of $24.19. Analysts anticipate Catalyst Pharmaceuticals Inc stock to reach 33 by 2025, with the lowest price target being 33. In spite of this, 3 analysts ranked Catalyst Pharmaceuticals Inc stock as Buy at the end of 2025. On December 21, 2023, Oppenheimer assigned a price target of “an Outperform” to the stock and initiated coverage with a $30.
